PMID- 19443377
OWN - NLM
STAT- MEDLINE
DCOM- 20090817
LR  - 20181201
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 29
IP  - 5
DP  - 2009 May
TI  - Management of cardiac adverse events occurring with sunitinib treatment.
PG  - 1627-9
AB  - BACKGROUND: Sunitinib malate is the reference standard of care for the first-line 
      treatment of metastatic renal cell carcinoma (mRCC). Cardiovascular adverse 
      events (AEs) have been observed with sunitinib treatment. Here, we present the 
      case report of a 49-year-old male patient with mRCC in whom cardiac AEs 
      experienced during sunitinib treatment were successfully managed. The patient was 
      at poor prognostic risk, with an Eastern Cooperative Oncology Group performance 
      status of 3. RESULTS: The patient was treated with sunitinib 50 mg/day (4 weeks 
      on treatment followed by 2 weeks off treatment; Schedule 4/2) following lung and 
      bone metastases. Cardiac AEs occurred following sunitinib initiation. These 
      events were resolved with cardiovascular co-medication. Sunitinib improved the 
      patient's quality of life and performance status, with a prolonged duration of 
      treatment of 24 months. CONCLUSION: This case indicates that cardiac AEs should 
      not be a barrier to the effective use of sunitinib in mRCC.
FAU - Schmidinger, Manuela
AU  - Schmidinger M
AD  - Medical University of Vienna, Department of Medicine I and Cancer Center, 
      Clinical Division of Oncology, Waehringer Guertel 18-20, A-1090 Vienna, Austria. 
      manuela.schmidinger@meduniwien.ac.at
FAU - Bojic, Andja
AU  - Bojic A
FAU - Vogl, Ursula M
AU  - Vogl UM
FAU - Lamm, Wolfgang
AU  - Lamm W
FAU - Zielinski, Christoph C
AU  - Zielinski CC
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Diuretics)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Diuretics/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Heart/*drug effects
MH  - Humans
MH  - Indoles/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Pyrroles/*adverse effects
MH  - Sunitinib
EDAT- 2009/05/16 09:00
MHDA- 2009/08/18 09:00
CRDT- 2009/05/16 09:00
PHST- 2009/05/16 09:00 [entrez]
PHST- 2009/05/16 09:00 [pubmed]
PHST- 2009/08/18 09:00 [medline]
AID - 29/5/1627 [pii]
PST - ppublish
SO  - Anticancer Res. 2009 May;29(5):1627-9.